Lyell Immunopharma's total assets for Q4 2024 were $490.86M, a decrease of -20.73% from the previous quarter. LYEL total liabilities were $108.03M for the fiscal quarter, a 22.05% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.